AceLink Therapeutics is dedicated to developing novel drugs for both rare and common genetic diseases. The AceLink team is comprised of a streamlined group of experienced drug development scientists and consultants, which allows us to efficiently evaluate and rapidly advance therapeutic candidates.   While our initial focus is on developing therapies for kidney diseases, AceLink’s goal is to diversify the pipeline to address the unmet clinical need for a broader set of genetic diseases.

More than 60 genetic diseases are currently known to directly or indirectly affect kidney function. These diseases range from relatively common to very rare and can impact kidney functions in infants to adults. Many of these diseases are progressive and eventually lead to chronic kidney disease (CKD) and end stage renal disease (ESRD). Unfortunately, for the majority there are no disease modifying therapeutic options and patients eventually resort to renal replacement therapies (RRT) including chronic dialysis or transplant. With their high prevalence and limited therapeutic options, these kidney diseases present a significant health care and economic challenge

© Copyright AceLink Therapeutics. All rights reserved